MDM2-PROTAC versus MDM2 Inhibitors: Beyond p53 Reactivation

被引：9

作者：

Peuget, Sylvain ^{[1
]}

Selivanova, Galina ^{[1
,2
]}

机构：

[1] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden

[2] Karolinska Inst, Biomedicum C8,Solnavagen 9, S-17165 Stockholm, Sweden

来源：

CANCER DISCOVERY | 2023年 / 13卷 / 05期

关键词：

D O I：

10.1158/2159-8290.CD-23-0229

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In this issue of Cancer Discovery , Adams and colleagues present the discovery of a potent PROTAC, MDM2 degrader, which activates wild-type p53 leading to cancer cell death. Importantly, in a number of in vitro and in vivo experiments, the authors show that the depletion of MDM2 by PROTAC kills p53-mutant or p53-null cancer cells.

引用

页码：1043 / 1045

页数：3

共 50 条

[1] P53 Mdm2 Inhibitors
Khoury, Kareem
Doemling, Alex
CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (30) : 4668 - 4678
[2] p53 ubiquitination: Mdm2 and beyond
Brooks, CL
Gu, W
MOLECULAR CELL, 2006, 21 (03) : 307 - 315
[3] Reactivation of p53 via MDM2 inhibition
Kim, E. S.
Shohet, J. M.
CELL DEATH & DISEASE, 2015, 6 : e1936 - e1936
[4] Reactivation of p53 via MDM2 inhibition
E S Kim
J M Shohet
Cell Death & Disease, 2015, 6 : e1936 - e1936
[5] Reactivation of p53 by novel MDM2 inhibitors for pancreatic cancer therapy
Azmi, Asfar
Philip, Philip
Wang, Zhiwei
Ahmad, Aamir
Wu, Jiusheng
Aboukameel, Amro
Yang, Dajun
Wang, Shaomeng
Sarkar, Fazlul
Mohammad, Ramzi
CANCER RESEARCH, 2009, 69
[6] Binding of an inhibitor of the p53/MDM2 interaction to MDM2
Duncan, SJ
Cooper, MA
Williams, DH
CHEMICAL COMMUNICATIONS, 2003, (03) : 316 - 317
[7] The Dual Interactions of p53 with MDM2 and p300: Implications for the Design of MDM2 Inhibitors
Kannan, Srinivasaraghavan
Partridge, Anthony W.
Lane, David P.
Verma, Chandra S.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (23)
[8] Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment
Gupta, Amit
Shah, Karan
Oza, Manisha J.
Behl, Tapan
BIOMEDICINE & PHARMACOTHERAPY, 2019, 109 : 484 - 492
[9] Fortifying p53-beyond Mdm2 inhibitors
Sriraman, Anusha
Li, Yizhu
Dobbelstein, Matthias
AGING-US, 2016, 8 (09): : 1836 - 1837
[10] Reactivation of p53 by Novel MDM2 Inhibitors: Implications for Pancreatic Cancer Therapy
Azmi, A. S.
Philip, P. A.
Aboukameel, A.
Wang, Z.
Banerjee, S.
Zafar, S. F.
Goustin, A. -S.
Almhanna, K.
Yang, D.
Sarkar, F. H.
Mohammad, R. M.
CURRENT CANCER DRUG TARGETS, 2010, 10 (03) : 319 - 331

← 1 2 3 4 5 →